- NEWS AND VIEWS
Genetics and anatomy sculpt immune-cell partners of ovarian cancer
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 612, 634-636 (2022)
doi: https://doi.org/10.1038/d41586-022-04169-3
References
Kurman, R. J. Ann. Oncol. 24, x16–x21 (2013).
Vázquez-García, I. et al. Nature 612, 778–786 (2022).
The Cancer Genome Atlas Research Network. Nature 474, 609–615 (2011).
Kandalaft, L. E., Dangaj Laniti, D. & Coukos, G. Nature Rev. Cancer 22, 640–656 (2022).
McPherson, A. et al. Nature Genet. 48, 758–767 (2016).
Zhang, A. W. et al. Cell 173, 1755–1769 (2018).
Bruand, M. et al. Cell Rep. 36, 109412 (2021).
Zhang, L. et al. N. Engl. J. Med. 348, 203–213 (2003).
Dangaj, D. et al. Cancer Cell 35, 885–900 (2019).
Duraiswamy, J. et al. Cancer Cell 39, 1623–1642 (2021).
Ding, L. et al. Cell Rep. 25, 2972–2980 (2018).
Peng, D. et al. Nature 527, 249–253 (2015).
Competing Interests
G.C. has received grants, research support or is co-investigator in clinical trials by Bristol-Myers Squibb, Celgene, Boehringer Ingelheim, Roche, Tigen Pharma, Iovance and Kite. G.C. has patents in the domain of antibodies and vaccines targeting the tumour vasculature, as well as technologies related to T-cell expansion and engineering for T-cell therapy.